DBM

UPCOMMaterials

Dược - Vật tư Y tế Đăk Lăk Joint Stock Company

Original Name: Công ty Cổ phần Dược - Vật tư Y tế Đăk Lăk

Reference Price28.000 ₫

Interactive Stock Chart

Exchange Ticker: UPCOM:DBM

Listing Information

Exchange MarketUPCOM

Live SectorChemicals

First Trading Date17/12/2009

First Close Price₫33,000

Capital Structure

Charter Capital19.42 Billion VND

Listed Shares1,941,588

Outstanding Shares1,941,584

Treasury Shares-

Professional Advisors & Auditors

Independent Auditing History

Fiscal Year	Auditing Organization
2024	EY Vietnam Co., Ltd.
2023	EY Vietnam Co., Ltd.
2022	EY Vietnam Co., Ltd.
2021	EY Vietnam Co., Ltd.
2020	Deloitte Vietnam Co., Ltd.
2019	Deloitte Vietnam Co., Ltd.
2018	EY Vietnam Co., Ltd.
2017	EY Vietnam Co., Ltd.

IPO & Listing Consultant

Securities Ngân hàng TMCP Ngoại thương Vietnam Co., Ltd.Listing Ticker Symbol: VCBS

Detailed Corporate Timeline & Sectors

Establishment History:

Dak Lak Pharmaceutical - Medical Supplies Joint Stock Company (BAMEPHARM for short) was established on April 14, 1976 according to decision No. 28/QD-TC of the Revolutionary People's Committee of Daklak province with the name Daklak Pharmaceutical Company. After Timeline of Establishment & Development, the Company has expanded its scale and undergone the following name changes:
On August 12, 1982, the name was changed to Daklak Pharmaceutical Joint Enterprise according to Decision No. 355/QD-UB of the People's Committee of Daklak province on the basis of merging the Pharmaceutical Company and the local pharmaceutical factory.
On December 21, 1992, the name was changed to Daklak Pharmaceutical and Medical Supplies Company according to Decision No. 860/QD-UB of the Daklak Provincial People's Committee on the basis of merging the Pharmaceutical Enterprise, Medical Equipment and Supplies Company and Level III Pharmaceutical Companies in the province.
On December 3, 2003, implementing the Government's policy on converting state-owned enterprises into joint stock companies, the Company's new name was Dak Lak Pharmaceutical - Medical Supplies Joint Stock Company.
August 2010: The company listed on Upcom

Business Sectors:

Producing medicines to treat human diseases, nutritional food products, and medicines derived from medicinal herbs.
Buy and sell drugs, pharmaceuticals, vaccines-biological products, chemicals of all kinds and nutritional food products.
Buying and selling optical equipment, medical equipment, dental equipment, hospital equipment.
Repair and warranty services for machinery and specialized medical equipment.
Affordable accommodation services, commercial activities and services.
Growing medicinal plants, processing medicinal herbs.
Export and import of drugs, medicinal materials and medical equipment.

Address: 9A Hung Vuong, City. Buon Ma Thuot, Daklak Province

Phone: 0262 381 23 94 Fax: 0262 385 88 05

Disclosure Officer:

Email: [email protected]

Website: http://bamepharm.com.vn

Ratio / Financial Indicator	2022	2023	2024	2025
Earnings Per Share (EPS)	₫3,254	₫2,894	₫1,439	₫2,392
Price-to-Earnings (P/E)	8.60x	9.68x	19.45x	11.71x
Book Value Per Share (BVPS)	₫35,100	₫35,675	₫34,848	₫35,809
Price-to-Book (P/B)	0.80x	0.78x	0.80x	0.78x
Return on Equity (ROE)	9.27%	8.11%	4.13%	6.68%
Return on Assets (ROA)	5.79%	5.30%	2.78%	4.40%
Net Profit Margin	2.45%	2.38%	1.31%	2.12%
Debt-to-Equity Ratio	0.60	0.53	0.49	0.52
Current Ratio	2.56	2.76	2.91	2.78

Audited Financial Statements

Source: KB Securities (KBS) Datafeed • Updated dynamically

Show absolute values (VND)

Doanh thu thuần về bán hàng và cung cấp dịch vụNet revenue

-14.9% YoY

Lợi nhuận sau thuế thu nhập doanh nghiệpNet profit after tax

-26.5% YoY

TỔNG CỘNG TÀI SẢNTOTAL ASSETS

-3.3% YoY

Financial Indicator (VND)	2025	2024	2023	2022
1. Doanh thu bán hàng và cung cấp dịch vụ 1. Revenue	219,928,386,000	213,371,815,000	236,691,259,000	258,864,889,000
2. Các khoản giảm trừ doanh thu2. Deduction from revenue	605,092,000	324,673,000	333,266,000	1,100,393,000
3. Doanh thu thuần về bán hàng và cung cấp dịch vụ3. Net revenue	219,323,294,000	213,047,142,000	236,357,993,000	257,764,496,000
4. Giá vốn hàng bán 4. Cost of goods sold	196,534,352,000	193,220,519,000	212,833,208,000	229,446,287,000
5. Lợi nhuận gộp về bán hàng và cung cấp dịch vụ5. Gross profit	22,788,941,000	19,826,624,000	23,524,785,000	28,318,209,000
6. Lãi/Lỗ của hoạt động bán, thanh lý bất động sản đầu tư6. Gain/(Loss) on disposal of investment property	-	-	-	-
7. Doanh thu hoạt động tài chính 7. Financial income	3,072,798,000	2,898,842,000	2,568,086,000	1,867,309,000
8. Chi phí tài chính 8. Financial expenses	403,379,000	362,239,000	398,999,000	510,492,000
Trong đó: Chi phí đi vay Of which: Interest expense	-	3,068,000	5,756,000	-
8. Phần lãi/lỗ trong công ty liên doanh, liên kết8. Share of associates and joint ventures' result	-	-	-	-
9. Chi phí bán hàng 9. Selling expenses	11,401,207,000	10,980,247,000	11,312,704,000	13,625,969,000
10. Chi phí quản lý doanh nghiệp 10. General and administrative expenses	8,812,821,000	8,743,175,000	8,519,494,000	9,699,379,000
11. Lợi nhuận thuần từ hoạt động kinh doanh11. Operating profit	5,244,332,000	2,639,804,000	5,861,674,000	6,349,678,000
12. Thu nhập khác 12. Other income	436,441,000	709,343,000	1,173,916,000	1,548,863,000
13. Chi phí khác 13. Other expenses	14,579,000	1,133,000	34,760,000	18,164,000
14. Lợi nhuận khác14. Other profit	421,862,000	708,210,000	1,139,156,000	1,530,699,000
Phần lợi nhuận/lỗ từ công ty liên kết liên doanhShare of associates and joint ventures' result	-	-	-	-
15. Tổng lợi nhuận kế toán trước thuế15. Profit before tax	5,666,194,000	3,348,014,000	7,000,830,000	7,880,378,000
16. Chi phí thuế TNDN hiện hành16. Current corporate income tax expenses	1,021,842,000	534,937,000	1,382,318,000	1,448,506,000
17. Chi phí thuế TNDN hoãn lại 17. Deferred income tax expenses (*)	-	18,226,000	-	113,865,000
18. Lợi nhuận sau thuế thu nhập doanh nghiệp18. Net profit after tax	4,644,352,000	2,794,851,000	5,618,512,000	6,318,006,000
Lợi ích của cổ đông thiểu sốMinority Interest	-	-	-	-
Lợi nhuận sau thuế của cổ đông của Công ty mẹProfit after tax for shareholders of parent company	4,644,352,000	2,794,851,000	5,618,512,000	6,318,006,000
19. Lãi cơ bản trên cổ phiếu (VNÐ)19. Earnings per share (VND)	2,392	1,439	2,894	3,254
20. Lãi suy giảm trên cổ phiếu (*)20. Diluted earnings per share	2,000	1,000	3,000	3,000

Data Source & Disclaimer

Data Source: Financial statement data is automatically aggregated from official disclosure feeds of listed companies through the analysis system of KB Securities Vietnam JSC (KB Securities).

Disclaimer: All financial data displayed on this website is provided for general reference purposes only. We make every effort to update accurate data but do not provide any warranty regarding its completeness or absolute reliability. The displayed figures do not constitute investment advice or an offer to trade securities. Users assume all risks and responsibilities for any financial decisions made based on the data on this website.

DBM

Dược - Vật tư Y tế Đăk Lăk Joint Stock Company

Interactive Stock Chart

Listing Information

Capital Structure

Professional Advisors & Auditors

Independent Auditing History

IPO & Listing Consultant

Detailed Corporate Timeline & Sectors

Key Financial Ratios (2025)

Historical Financial Metrics (YoY)

Financial Ratios Reference & Interpretation Guide

Audited Financial Statements

DBM — Financial Data Summary (2022–2025)

Executive Summary

Operating Performance & Profitability

Asset Structure & Financial Leverage

Cash Flow Quality